Nothing Special   »   [go: up one dir, main page]

PL2046787T3 - Związki pirazolo[3,4-b]pirydynowe i ich zastosowanie jako inhibitory PDE4 - Google Patents

Związki pirazolo[3,4-b]pirydynowe i ich zastosowanie jako inhibitory PDE4

Info

Publication number
PL2046787T3
PL2046787T3 PL07766400T PL07766400T PL2046787T3 PL 2046787 T3 PL2046787 T3 PL 2046787T3 PL 07766400 T PL07766400 T PL 07766400T PL 07766400 T PL07766400 T PL 07766400T PL 2046787 T3 PL2046787 T3 PL 2046787T3
Authority
PL
Poland
Prior art keywords
pyrazolo
salt
pde4 inhibitors
pyridine compounds
allergic
Prior art date
Application number
PL07766400T
Other languages
English (en)
Inventor
David George Allen
Nicola Mary Aston
Rodger Phillip Barnett
Reshma Manesh Chudasama
Caroline Jane Day
Christopher David Edlin
Leanda Jane Kindon
Naimisha Trivedi
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0615286A external-priority patent/GB0615286D0/en
Priority claimed from GB0706790A external-priority patent/GB0706790D0/en
Priority claimed from GB0714815A external-priority patent/GB0714815D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PL2046787T3 publication Critical patent/PL2046787T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL07766400T 2006-08-01 2007-07-31 Związki pirazolo[3,4-b]pirydynowe i ich zastosowanie jako inhibitory PDE4 PL2046787T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0615286A GB0615286D0 (en) 2006-08-01 2006-08-01 Compounds
GB0706790A GB0706790D0 (en) 2007-04-05 2007-04-05 Compounds
GB0714815A GB0714815D0 (en) 2007-07-30 2007-07-30 Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors
EP07766400A EP2046787B1 (en) 2006-08-01 2007-07-31 Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
PCT/GB2007/002908 WO2008015416A1 (en) 2006-08-01 2007-07-31 Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors

Publications (1)

Publication Number Publication Date
PL2046787T3 true PL2046787T3 (pl) 2011-10-31

Family

ID=38996907

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07766400T PL2046787T3 (pl) 2006-08-01 2007-07-31 Związki pirazolo[3,4-b]pirydynowe i ich zastosowanie jako inhibitory PDE4

Country Status (18)

Country Link
US (3) US8003663B2 (pl)
EP (1) EP2046787B1 (pl)
JP (1) JP2009545579A (pl)
AT (1) ATE504586T1 (pl)
AU (1) AU2007280214A1 (pl)
CA (1) CA2659539A1 (pl)
CL (1) CL2007002349A1 (pl)
CY (1) CY1111625T1 (pl)
DE (1) DE602007013762D1 (pl)
DK (1) DK2046787T3 (pl)
HK (1) HK1127603A1 (pl)
HR (1) HRP20110434T1 (pl)
NZ (1) NZ574533A (pl)
PL (1) PL2046787T3 (pl)
PT (1) PT2046787E (pl)
SI (1) SI2046787T1 (pl)
TW (1) TW200840818A (pl)
WO (2) WO2008015416A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007280214A1 (en) 2006-08-01 2008-02-07 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors
ES2605582T3 (es) * 2009-04-17 2017-03-15 Merz Pharma Gmbh & Co. Kgaa Síntesis de mesilato de 1-amino-1,3,3,5,5-pentametilciclohexano
UY33373A (es) 2010-05-10 2011-12-30 Gilead Sciences Inc ?Compuestos de pirazolopiridina bifuncionales, su uso en terapia y composiciones que los comprenden?.
US9597312B2 (en) * 2010-08-19 2017-03-21 Cognitive Research Enterprises, Inc. Treatment of cognitive disorders associated with abnormal dendritic spines using PKC activators
EP2628730B1 (en) * 2012-02-16 2017-12-06 Noxell Corporation Telescoping synthesis of 5-amino-4-nitroso-1-alkyl-1h-pyrazole salts
US9011934B2 (en) 2013-06-14 2015-04-21 SatisPharma, LLC Multi-purpose anti-itch treatment
US9452178B1 (en) 2014-10-22 2016-09-27 SatisPharma, LLC Acne formulations, treatments, and pressure sensitive patches for delivery of acne formulations
DE102015000626A1 (de) * 2015-01-22 2016-07-28 Kibion Gmbh Verfahren zum Nachweis von Helicobacter Pylori
CN111732543A (zh) * 2020-08-14 2020-10-02 浙江鼎龙科技有限公司 一种4,5-二氨基-1-（2-羟乙基）吡唑硫酸盐的制备方法

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3200123A (en) 1962-01-26 1965-08-10 Richardson Merreil Inc Imidazoquinolines
JPS4824396B1 (pl) 1970-09-09 1973-07-20
BE887518A (fr) 1980-02-15 1981-08-13 Glaxo Group Ltd Cartothioates d'androstanes
DE3927761C2 (de) 1989-08-23 1997-11-27 Huels Chemische Werke Ag Verfahren zur Herstellung von Alkoxyalkylidenmalonsäureestern
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
GB9127376D0 (en) 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
DE69434492T2 (de) 1993-03-10 2006-07-13 Smithkline Beecham Corp. Phosphodiesterase des menschlichen gehirns
WO1994021229A1 (en) 1993-03-17 1994-09-29 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
SI0957087T1 (en) 1994-06-15 2003-04-30 The Wellcome Foundation Limited Intermediates useful in the preparation of enzyme inhibitors
EP0832069B1 (en) 1995-06-07 2003-03-05 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
PL330465A1 (en) 1996-06-17 1999-05-24 Smithkline Beecham Plc Substituted benzamide derivatives and their application as anticonvulsants
MY117948A (en) 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
AU737955B2 (en) 1997-03-18 2001-09-06 Smithkline Beecham Plc Substituted isoquinoline derivatives and their use as anticonvulsants
AUPO622597A0 (en) 1997-04-15 1997-05-08 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
JPH11174621A (ja) 1997-10-08 1999-07-02 Fuji Photo Film Co Ltd 熱現像写真感光材料
GB9811599D0 (en) 1998-05-30 1998-07-29 Glaxo Group Ltd Nitric oxide synthase inhibitors
EP1283036B2 (de) 1998-11-13 2020-01-01 Jagotec AG Multidosis-Trockenpulverinhalator mit Pulverreservoir
PL196951B1 (pl) 1999-03-05 2008-02-29 Chiesi Farma Spa Proszek do stosowania w inhalatorze suchego proszku, cząsteczki nośnika i sposób wytwarzania nośnika
CA2373510A1 (en) 1999-05-12 2000-11-23 Ortho-Mcneil Pharmaceutical, Inc. Pyrazole carboxamides useful for the treatment of obesity and other disorders
WO2001021577A2 (en) 1999-09-20 2001-03-29 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist
CA2325358C (en) 1999-11-10 2005-08-02 Pfizer Products Inc. 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
US6531478B2 (en) 2000-02-24 2003-03-11 Cheryl P. Kordik Amino pyrazole derivatives useful for the treatment of obesity and other disorders
US20020052312A1 (en) 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
AU8066701A (en) 2000-07-20 2002-02-05 Neurogen Corp Capsaicin receptor ligands
ES2546830T3 (es) 2000-08-05 2015-09-29 Glaxo Group Limited Éster S-fluorometilo del ácido 6alfa,9alfa-difluoro-17alfa-[(2-furanilcarboxil)oxi]-11beta-hidroxi-16alfa-metil-3-oxo-androsta-1,4-dieno-17beta-carbotioico como agente antiinflamatorio
US20020193393A1 (en) 2001-03-07 2002-12-19 Michel Pairet Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
DE10110772A1 (de) 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
GB0031179D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Nitric oxide synthase inhibitors
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
ATE365720T1 (de) 2001-03-08 2007-07-15 Glaxo Group Ltd Agonisten von beta-adrenorezeptoren
ATE381537T1 (de) 2001-03-22 2008-01-15 Glaxo Group Ltd Formanilid-derivative als beta2-adrenorezeptor- agonisten
GB0118373D0 (en) 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
PT2042168E (pt) 2001-09-14 2014-01-03 Glaxo Group Ltd Formulação de inalação compreendendo derivados de fenetanolamina para o tratamento de doenças respiratórias
GB0123951D0 (en) 2001-10-05 2001-11-28 Glaxo Group Ltd Therapies for treating respiratory diseases
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
GB0208608D0 (en) 2002-04-13 2002-05-22 Glaxo Group Ltd Composition
AU2003222841A1 (en) 2002-04-25 2003-11-10 Glaxo Group Limited Phenethanolamine derivatives
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
CN100387598C (zh) 2002-09-16 2008-05-14 葛兰素集团有限公司 吡唑并[3,4-b]吡啶化合物及其作为磷酸二酯酶抑制剂的用途
DE60315492T2 (de) 2002-10-22 2008-04-24 Glaxo Group Ltd., Greenford Medizinisch verwendbare arylethanolamin verbindungen
EP1556342B1 (en) 2002-10-28 2008-03-26 Glaxo Group Limited Phenethanolamine derivative for the treatment of respiratory diseases
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
AP2007004239A0 (en) 2003-10-14 2007-12-31 Glaxo Group Ltd Muscarinic acetycholine receptor antagonists
CN1901958B (zh) 2003-11-03 2011-03-09 葛兰素集团有限公司 流体分配装置
PE20050489A1 (es) 2003-11-04 2005-09-02 Glaxo Group Ltd Antagonistas de receptores de acetilcolina muscarinicos
US20070111995A1 (en) * 2003-12-19 2007-05-17 Allen David G Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors
GB0405933D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
GB0405937D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
RU2378274C2 (ru) 2004-03-16 2010-01-10 Глаксо Груп Лимитед ПИРАЗОЛО[3,4-b]ПИРИДИНОВОЕ СОЕДИНЕНИЕ И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРА ФДЭ4
AR050902A1 (es) 2004-04-27 2006-12-06 Glaxo Group Ltd Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
EP1940836A1 (en) 2005-09-29 2008-07-09 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor
AU2007280214A1 (en) 2006-08-01 2008-02-07 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors

Also Published As

Publication number Publication date
ATE504586T1 (de) 2011-04-15
CL2007002349A1 (es) 2008-10-10
SI2046787T1 (sl) 2011-07-29
CY1111625T1 (el) 2015-10-07
CA2659539A1 (en) 2008-02-07
US20090325952A1 (en) 2009-12-31
PT2046787E (pt) 2011-06-15
TW200840818A (en) 2008-10-16
EP2046787A1 (en) 2009-04-15
DK2046787T3 (da) 2011-07-18
HK1127603A1 (en) 2009-10-02
WO2008015437A1 (en) 2008-02-07
AU2007280214A1 (en) 2008-02-07
EP2046787B1 (en) 2011-04-06
HRP20110434T1 (hr) 2011-08-31
JP2009545579A (ja) 2009-12-24
DE602007013762D1 (de) 2011-05-19
NZ574533A (en) 2011-05-27
US20090318494A1 (en) 2009-12-24
US20080058369A1 (en) 2008-03-06
WO2008015416A1 (en) 2008-02-07
US8003663B2 (en) 2011-08-23

Similar Documents

Publication Publication Date Title
HK1127603A1 (en) Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
WO2004024728A3 (en) Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
MY151172A (en) Pyrimidine amide compounds as pgds inhibitors
TW200500364A (en) Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
GEP20104973B (en) Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
SG179437A1 (en) Pyrimidine hydrazide compounds as pgds inhibitors
NZ587039A (en) 6-aryl-imidazo[1, 2-a]pyrazine derivatives, method of making, and method of use thereof
TNSN08478A1 (en) Pyrazolo [3,4-d] pyrimidine derivatives useful to treat respiratory disorders
NO20063340L (no) Pyrazol-[3,4-B]-pyridinforbindelser, og deres anvendelse som fosfodiesteraseinhibitorer
WO2005021515A3 (en) Inhibitors of phosphodiesterase type-iv
WO2007071313A3 (en) Combination of anticholinergics, glucocorticoids, beta2-ag0nists, pde4 inhibitor and antileukotriene for the treatment of inflammatory diseases
NZ599099A (en) Phenyloxadiazole derivatives as pgds inhibitors
WO2008035315A3 (en) Inhibitors of phosphodiesterase type-iv
MY142090A (en) Substituted diaza-spiro-[5.5]-undecane derivatives and their use as neurokinin antagonists
JP2011519845A5 (pl)
TW200610529A (en) Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
MY135776A (en) PYRAZOLO [3,4-b] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS
PE20081835A1 (es) COMPUESTOS DE PIRAZOLO[3,4-b]PIRIDINA Y SU USO COMO INHIBIDORES DE LA PDE4
TH77766B (th) สารประกอบไพราโซโล [3,4-b]ไพริดีน, และการใช้พวกมันเสมือนเป็นตัวยับยั้งฟอสโฟไดเอสเทอเรส
TH104555A (th) สารประกอบไพราโซโล[3,4-b]ไพริดีน และการใช้ของมันเป็นตัวยับยั้ง PDE4
TH151346A (th) การใช้อนุพันธ์ไพเพอริดิน-4-อิลอะเซติดีนเป็นสารยับยั้ง jak1
TH77766A (th) สารประกอบไพราโซโล[3,4-b]ไพริดีน, และการใช้พวกมันเสมือนเป็นตัวยับยั้งฟอสโฟไดเอสเทอเรส
TH104555B (th) สารประกอบไพราโซล[3,4-b]ไพริดีน และการใช้ของมันเป็นตัวยับยั้ง PDE4
MY145168A (en) Substituted diaza-spiro-[4.5]-decane derivatives and their use as neurokinin antagonists